Nike Shares Drop despite Positive Quarter Results; Endocyte Almost Doubles on Cancer Drug Approval

Follow this company

Companies Mentioned

03/24/2014 [ACCESSWIRE]

Nike, Inc. (NYSE: NKE) - For an in-depth report on Nike, Inc. follow:

Nike shares closed down 5.12% on Friday with nearly 16 million shares traded. The stock was one of the most active stocks on the NYSE. The drop came despite a good earnings report. Motley Fool analyst Brendan Mathews thinks the quarter for the company was a good one. Revenue increased by 13%, and earnings per share grew by 4%, which slightly beat analysts' estimates.

Endocyte, Inc. (NASDAQ: ECYT) - For an in-depth report on Endocyte, Inc. follow:

Shares of Endocyte closed up 92.42% on Friday with nearly 16 million shares traded. The stock was one of the biggest gainers on the NASDAQ and hit a new high of $33.70 during intra-day trading. European Union regulators said the company's drug Vynfinit should be approved as a treatment for ovarian cancer, and Endocyte said the drug helped slow the progression of lung cancer in a midstage trial.

Astika Holdings, Inc. (OTCBB: ASKH) - For an in-depth report on Astika Holdings, Inc. follow:

ASKH closed down 13.75% on about 715,000 shares traded this past Friday. The stock was one of the biggest decliners in the OTCBB marketplace. The company announced last week that it is entering into the Industrial Hemp sector through partnerships with current leaseholders with the goal of acquiring operating facilities to begin its own facilities in Asia and New Zealand with the launch of Nantong HZ Hemp Co. Ltd.

Biogen Idec Inc. (NASDAQ: BIIB) - For an in-depth report on Biogen Idec Inc. follow:

Shares of BIIB closed down 8.22% on about 5.7 million shares traded. The stock fell much like others in the biotech sector, amid controversy tied to Gilead Sciences' hepatitis C drug Sovaldi. Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally.


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.


Leave a comment...

Your Name